Literature DB >> 29436689

MicroRNA-655 attenuates the malignant biological behaviours of retinoblastoma cells by directly targeting PAX6 and suppressing the ERK and p38 MAPK signalling pathways.

Min Zhang1, Qiongxia Li2, Yingzhe Pan1, Hui Wang1, Gang Liu1, Hui Yin1.   

Abstract

Numerous studies have indicated that microRNAs (miRNAs) regulate signalling molecules by acting as oncogenes or tumour-suppressor genes in retinoblastoma (RB). Therefore, investigation of the expression pattern, biological roles and associated mechanisms of cancer-related miRNAs in RB may provide novel therapeutic targets for patients with this disease. miRNA-655 (miR-655) has been reported to be aberrantly expressed in many types of cancers. However, the expression pattern, detailed biological function and underlying molecular mechanisms of miR-655 in RB remain to be clarified. Therefore, the aims of the present study were to detect miR-655 in RB, investigate its biological roles in RB and determine the underlying molecular mechanisms. The results of the present study showed that miR-655 was significantly downregulated in RB tissues and cell lines. Overexpression of miR-655 inhibited the proliferation and invasion ability while it increased the apoptosis of RB cells. Additionally, paired box 6 (PAX6) was identified as a direct target of miR-655 in RB. Furthermore, PAX6 was highly expressed in RB tissues and was negatively correlated with miR-655 expression. PAX6 knockdown recapitulated effects similar to those observed following miR-655 overexpression regarding the proliferation, invasion and apoptosis of RB cells. Rescue experiments demonstrated that restoration of PAX6 expression reversed the tumour-suppressing roles of miR-655 in RB cells. Moreover, upregulation of miR-655 reduced activation of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase signalling pathways in RB cells through PAX6 regulation. Therefore, restoration of miR-655 expression may be a promising therapeutic strategy for treating patients with RB in the future.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29436689     DOI: 10.3892/or.2018.6264

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   4.136


  6 in total

1.  Elevation of microRNA-365 impedes malignant behaviors of gastric cancer cells by inhibiting PAX6.

Authors:  Dan Hong; Aimin Zang; Zhiyu Wang; Lin Yang; Guanying Ren; Chong Zhang; Liwei Zhang; Wei Hou; Yaning Wei
Journal:  Funct Integr Genomics       Date:  2022-04-28       Impact factor: 3.674

Review 2.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

3.  Linc00963 Promote Cell Proliferation and Tumor Growth in Castration-Resistant Prostate Cancer by Modulating miR-655/TRIM24 Axis.

Authors:  Minghua Bai; Chenchen He; Shengjia Shi; Mincong Wang; Jinlu Ma; Pengtao Yang; Yiping Dong; Xingyi Mou; Suxia Han
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

4.  MicroRNA-9 inhibits proliferation and progression in retinoblastoma cells by targeting PTEN.

Authors:  Manhai Gao; Zhe Cui; Dan Zhao; Shurong Zhang; Qiang Cai
Journal:  Genes Genomics       Date:  2021-06-15       Impact factor: 1.839

5.  TRIM59 Promotes Retinoblastoma Progression by Activating the p38-MAPK Signaling Pathway.

Authors:  Chao Wu; Xue-Qin Shang; Zhi-Peng You; Qi-Fang Jin; Yu-Lan Zhang; Yue Zhou; Yue-Zhi Zhang; Ke Shi
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

6.  microRNA-181a-5p impedes the proliferation, migration, and invasion of retinoblastoma cells by targeting the NRAS proto-oncogene.

Authors:  Ming Ouyang; Guiqin Liu; Cheng Xiong; Jing Rao
Journal:  Clinics (Sao Paulo)       Date:  2022-03-24       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.